Upadacitinib

Drug Profile

Upadacitinib

Alternative Names: ABT-494

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Atopic dermatitis; Crohn's disease

Most Recent Events

  • 09 May 2017 Adverse events and efficacy data from a phase II Celest trial in Crohn's disease released by AbbVie
  • 12 Apr 2017 AbbVie initiates enrolment in a phase III trial for Psoriatic arthritis in USA (NCT03104400)
  • 01 Apr 2017 Phase-III clinical trials in Psoriatic arthritis (In adults, In the elderly, Treatment-experienced) in USA (PO) (NCT03104374)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top